TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02088671

Intervention type: DRUG
Intervention: Propofol induction followed by randomized doses of desflurane
Description: Anesthesia in all patients will be induced with iv propofol 1.5 mg/kg with extra 0.5 mg/kg doses as needed. Anesthesia will be maintained using inhaled desflurane in oxygen/air with the initial desflurane concentration of 1.2 MAC, which will be changed in steps of ±0.4 MAC after reaching the post-intubation steady state. The step changes will be initiated every 7.5 min, as follows: at every level of MAC there is a 1/3 chance in remaining at this level and a 2/3 chance of changing it. The anesthesiologist can accept the change to move to the new level. However, he/she can also reject it to remain at the current level for another 7.5 min. This scheme yields 3 possible desflurane levels: 0.8, 1.2 and 1.6 MAC. The anesthesiologist can also leave the randomization schedule at anytime if clinically indicated, and later re-start it at his/her discretion. All anesthetic doses and their changes fall within conventional dosing.

Intervention type: DEVICE
Intervention: Recording of EEG using NeuroSENSE
Description: The NeuroSENSE NS-701 system is a 2-channel device for brain activity monitoring in the operating room, intensive care unit, emergency room and other clinical settings. The system acquires and processes electroencephalograms (EEGs) via noninvasive electrodes placed on a patient's forehead. The acquired raw EEG signals and processed EEG variables are continuously displayed for interpretation by the clinician.~The proprietary processed variable, WAVcns, quantifies the patient's brain activity, which is typically affected by anesthetic drugs. The system displays processed variables based on 2 bilateral channels (1 per brain hemisphere) for use as a supplement to the anesthesia standard of care.~Note: the indications provided by the NeuroSENSE monitor are not used for anesthesia dosing or patient assessment in this study, and the anesthesia provider is blinded to the monitor readings. The device is used only for acquisition of EEG signals and may be used to log the events of interest.

Intervention type: OTHER
Intervention: Data collection
Description: Non-invasive blood pressure (BP), heart rate (HR), respiratory rate (RR) and electroencephalogram (EEG) will be recorded during the surgery in all subjects. Also, information about all medically significant events, all study-related events (incl. patient's reactions, responses, observations and assessments) and administered medications (incl. end-tidal (ET) desflurane concentration) will be recorded along with time stamps.~The anesthesia and physiological parameters (e.g., BP, HR, RR, ET agent concentration) outputted from the anesthesia monitor will be recorded electronically during the surgery by the anesthesia monitoring system (data-points will be recorded at least every 3 min for BP and every 10 sec for other variables).~The EEG signal will be continuously recorded by NeuroSENSE NS-701 Monitor (described under a separate intervention).~The CRC will also be present in the Operating Room (OR) to record and manage the recording of all the required information.
Study: NCT01143688

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo inhaler

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: placebo acupuncture
Study: NCT02077764

Intervention type: PROCEDURE
Intervention: OCT and coronary angiography

Intervention type: PROCEDURE
Intervention: Right heart cat.

Intervention type: RADIATION
Intervention: PET

Intervention type: PROCEDURE
Intervention: Echocardiography

Intervention type: PROCEDURE
Intervention: Echocardiography

Intervention type: PROCEDURE
Intervention: exercise test

Intervention type: OTHER
Intervention: blood samples
Study: NCT01418274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: danoprevir
Description: oral doses of danoprevir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: escitalopram
Description: oral doses of escitalopram

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: oral doses of ritonavir
Study: NCT02088671

Intervention type: OTHER
Intervention: Drug: Emergence by stepping down the desflurane ET
Description: Anesthesia will be reduced to facilitate rapid recovery at the discretion of the anesthesiologist, about 20 minutes before the end of surgery. The desflurane ET will be stepped down from 0.8 MAC by steps of 0.2 MAC approximately every 5 min during the Emergence.
Study: NCT00384839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine for injectable suspension
Description: Vidaza: 75 mg/m2 for 5 consecutive days (Days 1-5) of each 28 day cycle. A cycle will equal to 28 days. Patient will receive a maximum of 12 cycles.
Study: NCT01981941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin enacarbil
Description: Oral
Study: NCT00449137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic trioxide
Description: ATO will be administered at dose levels determined by the dose escalation scheme (section 4.2). Intra-venous (IV) infusion of ATO (mg/kg body weight) over 1-4 hours will be administered for 5 consecutive days (day 1 to day 5) during the first week, twice a week on weeks 2 and 3 (days 8, 11, 15, and 18), and only one day (day 22) of week 4. Treatment will continue for a maximum of 8 cycles, provided that the patient tolerates treatment and there is evidence of clinical benefit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Escalate 5-FU, starting at dose 1600 mg/m2. On day 8, 15, and 22 the assigned dose of 5 FU plus 500 mg/m2 of leucovorin will be administered over 24 hours intravenous infusion following the administration of arsenic trioxide. Treatment will continue for a maximum of 8 cycles, provided that the patient tolerates treatment and there is evidence of clinical benefit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin calcium
Description: On day 8, 15, and 22 the assigned dose of 5 FU plus 500 mg/m2 of leucovorin will be administered over 24 hours intravenous infusion following the administration of arsenic trioxide. Treatment will continue for a maximum of 8 cycles, provided that the patient tolerates treatment and there is evidence of clinical benefit.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plasma levels of elemental arsenic
Description: Pre-Treatment and and one hour post ATO on days 1, 5, 8, 11,15, 18, and 22

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Mononuclear Cells (PBMC) for mRNA analysis
Description: Peripheral blood samples (PAXgene Blood RNA tube, Qiagen, USA) will be obtained up to 2 weeks prior to start of treatment (same day as the first FNA) and one hour post ATO on days 1, 5, 8, 11,15, 18, and 22. Along with FNA an additional blood sample will be obtained on day 23 of every odd treatment cycle.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor Biopsy (Fine-Needle Aspiration)
Description: Pre-Treatment, Day 23 of Cycles 1, 3, 5, 7
Study: NCT03462732

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal tube
Description: Nasotracheal intubation will be done with endotracheal tube

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal tube
Description: Nasotracheal intubation will be done with endotracheal tube

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nelaton catheter
Description: plus nelaton catheter
Study: NCT03523468

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: uniportal sleeve lobectomy
Description: central lung cancer sleeve resection performed by uniportal VATS

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open sleeve lobectomy
Description: central lung cancer sleeve resection performed by open chest
Study: NCT00335452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: oral administration
Study: NCT01733290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A
Description: A total of 100 units of BoNT-A will be injected deeply into the external sphincter at the 3, 6, 9 and 12 o'clock positions in approximate equal aliquot.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline instillation
Description: Normal saline instillation
Study: NCT02526420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somavaratan
Description: Long-acting recombinant human growth hormone therapy administered subcutaneously once monthly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somavaratan
Description: Long-acting recombinant human growth hormone therapy administered subcutaneously once monthly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somavaratan
Description: Long-acting recombinant human growth hormone therapy administered subcutaneously once monthly
Study: NCT01091857

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STRIDE

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: STRIDE
Study: NCT01037517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Plerixafor will be administered at 23:00 of Day -1 to experimental subjects at a dose of 240 mcg/kg subcutaneously, and possibly repeated the following day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Observation: Nonintervention
Description: Nonintervention group, no drug will be given, observation only
Study: NCT01063621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW-6500
Description: Subcutaneous injection of 1 to 6 mg for the OFF state during 52 weeks
Study: NCT04138472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: intravenous dexmedetomidine 0.06mg/kg in 100ml normal saline 0.9% over 10minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fentanyl
Description: intravenous fentanyl at 2mcg/kg in 100ml saline over 10 minutes in induction room.
Study: NCT00335452

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetylsalicyclic acid (ASA)
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetylsalicyclic acid (ASA)
Description: oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetylsalicyclic acid (ASA)
Description: oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetylsalicyclic acid (ASA)
Description: oral administration
Study: NCT04138472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine
Description: intravenous lidocaine 1.5mg/kg in 100ml saline over 10 minutes in induction room.
Study: NCT02811146

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bilevel Positive Pressure Airway
Description: Heart rehabilitation with noninvasive ventilation, for 12 weeks, 3 times a week

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bilevel Positive Pressure Airway
Description: Heart rehabilitation with noninvasive ventilation, for 12 weeks, 3 times a week

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bilevel Positive Pressure Airway
Description: Heart rehabilitation with noninvasive ventilation, for 12 weeks, 3 times a week

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bilevel Positive Pressure Airway
Description: Heart rehabilitation with noninvasive ventilation, for 12 weeks, 3 times a week

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bilevel Positive Pressure Airway
Description: Heart rehabilitation with noninvasive ventilation, for 12 weeks, 3 times a week

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heart rehabilitation
Description: Heart rehabilitation, for 12 weeks, 3 times a week
Study: NCT02923804

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3
Description: 3x 1g capsules taken daily for 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Olive oil
Description: 3x 1g capsules taken daily for 6 months
Study: NCT01355588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac Tromethamine
Description: 30 mg Ketorolac Tromethamine intranasal (IN)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac Tromethamine with 4% Lidocaine hydrochloride (HCl)
Description: 30 mg Ketorolac Tromethamine with 4% Lidocaine HCl IN

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac Tromethamine with 5% Lidocaine HCl
Description: 30 mg Ketorolac Tromethamine with 5% Lidocaine HCl IN

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 mg Ketorolac Tromethamine with 6% Lidocaine HCl
Description: 30 mg Ketorolac Tromethamine with 6% Lidocaine HCl IN
Study: NCT00746122

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Open repair
Description: Standard treatment of emergency open surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EVAR
Description: Emergency endovascular aneurysm repair
Study: NCT00002611

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: dactinomycin

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: dactinomycin

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: dactinomycin

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: dactinomycin

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: dactinomycin

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: dactinomycin

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: filgrastim

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: filgrastim

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: filgrastim

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: filgrastim

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride
Description: Source and Pharmacology: An anthracycline antibiotic isolated from cultures of Streptomyces peucetius. Binds to DNA and inhibits nucleic acid synthesis, with its major lethal effect occurring during the S phase of the cell cycle. Has some topoisomerase II inhibitory activity. Since it is primarily excreted by the liver, any liver impairment may enhance toxicity. 40% to 50% is excreted in the bile; \<5% in the urine. The drug has a very short initial t½ of \<20 minutes and a terminal t½ of 17 hours. Animal studies indicate cytotoxic levels persist in tissue for as long as 24 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride
Description: Source and Pharmacology: An anthracycline antibiotic isolated from cultures of Streptomyces peucetius. Binds to DNA and inhibits nucleic acid synthesis, with its major lethal effect occurring during the S phase of the cell cycle. Has some topoisomerase II inhibitory activity. Since it is primarily excreted by the liver, any liver impairment may enhance toxicity. 40% to 50% is excreted in the bile; \<5% in the urine. The drug has a very short initial t½ of \<20 minutes and a terminal t½ of 17 hours. Animal studies indicate cytotoxic levels persist in tissue for as long as 24 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride
Description: Source and Pharmacology: An anthracycline antibiotic isolated from cultures of Streptomyces peucetius. Binds to DNA and inhibits nucleic acid synthesis, with its major lethal effect occurring during the S phase of the cell cycle. Has some topoisomerase II inhibitory activity. Since it is primarily excreted by the liver, any liver impairment may enhance toxicity. 40% to 50% is excreted in the bile; \<5% in the urine. The drug has a very short initial t½ of \<20 minutes and a terminal t½ of 17 hours. Animal studies indicate cytotoxic levels persist in tissue for as long as 24 hours.
Study: NCT02984306

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cherry powder

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT05304299

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cordyceps Cicadae Mycelia
Description: Cordyceps Cicadae Mycelia will be given to test its potential for alleviation of high intraocular pressure.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cordyceps Cicadae Mycelia
Description: Cordyceps Cicadae Mycelia will be given to test its potential for alleviation of high intraocular pressure.
Study: NCT03757455

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERAS protocol preoperative actions
Description: First appointment:~- Enlightenment on the benefits and objectives of the ERAS protocol~Call to the patient day before the surgery:~Discussing the course, benefits and goals of care in ERAS 4 dl PreOp drink before bedtime~Operation day:~Fluid intake allowed 2 hours before surgery 2 dl PreOP drink 2 h before cutting

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERAS protocol intraoperative actions
Description: Intraoperative:~Drains in the peripancreatic or perihepatic regions are not set unless the surgeon sees this particular reason The nasogastric tube is removed at the end of the surgery
Study: NCT04285008

Intervention type: DEVICE
Group type: OTHER
Intervention: Pure-Vu System
Description: The Pure-Vu System is Food and Drug Administration (FDA) approved device (K191220), intended to connect to standard colonoscopes to help facilitate intra-procedural cleaning of a poorly prepared colon by irrigating or cleaning the colon and evacuating the irrigation fluid (water), feces and other bodily fluids and matter, e.g. blood.
Study: NCT01280838

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hombre Seguro
Description: A theory-based intervention that uses principles of behavior change derived from Social Cognitive Theory (SCT), Cognitive Behavioral Therapy (CBT), Theory of Reasoned Action (TRA), and MI to increase clients' use of condoms with FSWs.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Didactic attention-control condition
Description: The didactic control condition is a modified version of the CDC's revised guidelines for HIV counseling, testing, and referral and materials from Mexico's National Center for AIDS Studies (CENSIDA). The one-session, 60-minute counseling intervention focuses on HIV and STI prevention, risk appraisal, and the development of a risk reduction plan.
Study: NCT01843192

Intervention type: DEVICE
Intervention: Endocutter
Study: NCT00522301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunoenzyme technique

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Study: NCT03488368

Intervention type: OTHER
Intervention: observation
Description: Observation of renal outcome parameters and adverse events in the follow-up beyond the 3-year trial phase of the original STOP-IgAN trial.

Intervention type: OTHER
Intervention: observation
Description: Observation of renal outcome parameters and adverse events in the follow-up beyond the 3-year trial phase of the original STOP-IgAN trial.
Study: NCT04562961

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Schizophrenia caregivers qualitative interview
Description: The semi-structured qualitative interview will be carried out in a focus group or individually for a period of 1 hour. Focus groups are a group interview technique, moderated by a neutral facilitator in the presence of an observer, which aims to collect information on a limited number of pre-defined questions. In this study we foresee groups of 4 to 5 subjects. Focus groups will be privileged because they allow a better elaboration of the participants and therefore a better collection of data. If the focus group is not possible, the visit will be done individually. This interview will be framework-guided and recorded in their entirety and anonymously using a dictaphone and then transcribed the objective verbatim on a computer using word processing software. These transcriptions will be called the verbatims. The source data recorded using a dictaphone will be stored in secure, locked cabinets located within the investigation center.
Study: NCT02742298

Intervention type: DEVICE
Group type: OTHER
Intervention: Muscle ultrasound
Description: Ultrasound images of limb muscles will be collected.

Intervention type: OTHER
Group type: OTHER
Intervention: Electrical Impedance Myography
Description: A painless current passes through the skin and surface electrodes are used to record the impedance through muscle.
Study: NCT02281448

Intervention type: DRUG
Group type: OTHER
Intervention: BIA 2-093

Intervention type: DRUG
Group type: OTHER
Intervention: BIA 2-093

Intervention type: DRUG
Group type: OTHER
Intervention: Contraceptives, Oral, Combined

Intervention type: DRUG
Group type: OTHER
Intervention: Contraceptives, Oral, Combined
Study: NCT02430402

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation in warm climate
Study: NCT03827057

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reconsolidation of Traumatic Memories (RTM)
Description: RTM is a trauma-focused, but not cognitive behavioral, therapy: it involves brief exposure to the trauma memory, but does rely on conscious responses to correct the symptoms of PTSD. RTM was first used to treat phobias in the 1970s, and has more recently been refined to focus on reconsolidation to update long-term memories, reconfiguring the salience structure of the original memory, and incorporating those changes into the overall memory structure. Reconsolidation is a neural mechanism for updating long-term memory, inserting new information that contradicts an essential element of the memory, which makes it possible to change the emotional tone and salience of the memory. It is hypothesized that RTM can thereby achieve quicker, greater, and more durable responses than with traditional exposure therapies.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged Exposure (PE)
Description: PE is a trauma-focused cognitive behavioral therapy (TFCBT) that depends on exposure to the feared stimulus as a central effector of change, utilizing extinction, which theorizes that if a trigger that previously elicited a fear response is presented enough times without reinforcement, the response fades. Previous researchers have shown that extinction involves the creation of a new blocking memory which prevents expression of the original fear memory. While PE has more evidence to support its efficacy in PTSD than other approaches, and a majority achieve a clinical response (e.g., decrease in CAPS score of 10 or more), many do not achieve complete remission of symptoms, and the blocking memory may be fragile, so subsequent triggers may result in relapse.